BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand. - 2Flu concerns grow in US as UK sees more cases among kids
- 3Esteem Stuffed Gaming Workstations to Consider
- 4Manual for Tracking down One of a kind Store Inns
- 5West Palm Beach Shorecrest, renderings of downtown waterfront condo
- 10 Natural products to Remember for Your Eating routine for a Better You
- Which sandwich do you find totally delectable? !
- The most effective method to Recognize a Great Lab Jewel
- Make your choice for the sweet that transports you to its nation of beginning!
- 5 things for parents to know about changes to kids vaccine schedule
- Manual for Conservative SUVs For Seniors
- Viruses aren’t all bad: In the ocean, some help fuel the food web – a new study shows how
- Poland identifies two Ukrainian suspects in railway sabotage blast
- Instructions to Plan for Your Teeth Substitution Methodology
